logo-loader
Moleculin Biotech Inc

Moleculin Biotech looks to treat worlds toughest cancers with therapies

Moleculin Biotech (NASDAQ: MBRX) Founder, President and CEO Walter Klemp sat down with Christine Corrado from Proactive Investors New York to talk about their company that is looking for treatments for some of the toughest cancers to fight including Pancreatic.

Klemp telling Proactive,  Moleculin has just raised 15 million dollars which will allow them to continue their trials for the next 18 months/  

Quick facts: Moleculin Biotech Inc

Price: $1.15

Market: NASDAQ
Market Cap: $51.98 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Sarama Resources is well funded with an interesting project...

Sarama Resources (CVE: SWA) CEO Andrew Dinning sat down with Steve Darling from Proactive Vancouver to discuss the company and its' 100% owned South Houndé Project which is located situated in the prolific Houndé Belt. Dinning talked about the work that has been done there in the past and...

4 hours, 20 minutes ago

2 min read